FDA: no "clear connection" between Fosamax and hip fractures

The drug Fosamax (alendronate) and other oral bisphosponates are widely prescribed as a treatment for osteoporosis - and as a preventive measure.  Ironically jaw bone damage is a now-recognized complication.  Recent reports  have suggested that it may increase the rate of serious hip fractures.  The FDA is not yet ready to jump on that bandwagon.  It reports in an advisory HERE that "At this point, the data that FDA has reviewed have not shown a clear connection between bisphosphonate use and a risk of atypical subtrochanteric femur fractures. "